1. Home
  2. PRPL vs VTGN Comparison

PRPL vs VTGN Comparison

Compare PRPL & VTGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Purple Innovation Inc.

PRPL

Purple Innovation Inc.

N/A

Current Price

$2.77

Market Cap

34.1M

ML Signal

N/A

Logo VistaGen Therapeutics Inc.

VTGN

VistaGen Therapeutics Inc.

N/A

Current Price

$0.23

Market Cap

10.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PRPL
VTGN
Founded
2010
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Home Furnishings
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
34.1M
10.8M
IPO Year
2015
2014

Fundamental Metrics

Financial Performance
Metric
PRPL
VTGN
Price
$2.77
$0.23
Analyst Decision
Hold
Hold
Analyst Count
2
3
Target Price
$0.65
$0.90
AVG Volume (30 Days)
31.5K
513.6K
Earning Date
04-28-2026
06-16-2026
Dividend Yield
N/A
N/A
EPS Growth
152.75
N/A
EPS
N/A
N/A
Revenue
$468,725,000.00
N/A
Revenue This Year
$8.50
$124.49
Revenue Next Year
$6.68
$353.99
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.28
$0.20
52 Week High
$10.00
$5.14

Technical Indicators

Market Signals
Indicator
PRPL
VTGN
Relative Strength Index (RSI) 25.77 39.72
Support Level $0.40 $0.23
Resistance Level $10.00 $0.32
Average True Range (ATR) 0.23 0.01
MACD -0.16 0.00
Stochastic Oscillator 4.61 15.64

Price Performance

Historical Comparison
PRPL
VTGN

About PRPL Purple Innovation Inc.

Purple Innovation Inc designs and manufactures sleep products. Using its GelFlex Grid technology, the company designs, manufactures, and offers branded comfort sleep products, including mattresses, pillows, cushions, mattress protectors, bases, sheets, and others. It markets and sells these products through direct-to-consumer e-commerce channels, retail brick-and-mortar wholesale partners, Purple showrooms, and third-party online retailers.

About VTGN VistaGen Therapeutics Inc.

Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.

Share on Social Networks: